Pramlintide dosage: reported doses and schedule
A diabetes medicine that copies a hormone released with insulin; Symlin products are discontinued.
Also called: Symlin, SymlinPen, Pramlintide acetate, AC137, AC-0137, Tripro-amylin.
Amylin analogues · Short-acting amylin receptor agonist · Evidence: Approved drug.
Typical reported dose: Type 1 diabetes: starts at 15 mcg before meals, up to 60 mcg
- Symlin label: type 1 diabetes: 15 mcg before each major meal, then 30 mcg before each major meal, then 45 mcg before each major meal, then 60 mcg before each major meal immediately before each major meal, under the skin. Drug label. Studied in: Adults with type 1 diabetes using mealtime insulin. (source)
- Symlin label: type 2 diabetes: 60 mcg before each major meal, then 120 mcg before each major meal immediately before each major meal, under the skin. Drug label. Studied in: Adults with type 2 diabetes using mealtime insulin. (source)
- Early trial: 30 mcg per meal: 30 mcg before each meal three times daily before meals, under the skin. Studied in a trial. Studied in: Adults with type 1 diabetes. (source)
- Early trial: 100 mcg per meal: 100 mcg before each meal three times daily before meals, under the skin. Studied in a trial. Studied in: Adults with type 1 diabetes. (source)
- Early trial: 300 mcg per meal: 300 mcg before each meal three times daily before meals, under the skin. Studied in a trial. Studied in: Adults with type 1 diabetes. (source)
- 30 mcg four times daily: 30 mcg subcutaneously four times daily four times daily, under the skin. Studied in a trial. Studied in: Insulin-using adults with type 2 diabetes. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to Pramlintide
- Cagrilintide: An unapproved weekly amylin analogue with weight-loss trials and common stomach symptoms.
- CagriSema: An unapproved cagrilintide–semaglutide combination with phase 3 weight-loss and diabetes results.
- Semaglutide: A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
- Dulaglutide: A weekly GLP-1 medicine approved for type 2 diabetes and lower heart-event risk.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- Download medicine data, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Australian Register of Therapeutic Goods (ARTG), Therapeutic Goods Administration · TGA
- Drug Product Database: Access the database, Health Canada · Health Canada
- Drugs@FDA: SYMLIN, NDA 021332, FDA
- FD&C Act Provisions that Apply to Human Drug Compounding, FDA · FDA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.